Skip to main content
. 2018 Jan 1;9(1):43–54.

Figure 1.

Figure 1

Treatment options for hormonal therapy of advanced, hormone receptor–positive breast cancer in postmenopausal women. Modified from American Society of Clinical Oncology Guidelines (Rugo et al., 2016). As of January 2016, the combination therapies approved to treat advanced breast cancer in the United States are: letrozole + palbociclib, fulvestrant + palbociclib, and exemestane + everolimus. AI = aromatase inhibitor. a Early relapse, ≤ 12 months after adjuvant hormonal therapy; late relapse, > 12 months after adjuvant hormonal therapy.